The present invention in certain embodiments generally relates to an immunogenic composition comprising Bordetella sp. Adenylate cyclase toxin (CyaA) for use in treating Bordetella bronchiseptica infections in non-human animals. More particularly, the present disclosure relates to an immunogenic composition comprising Bordetella sp. Adenylate cyclase toxin (CyaA) vector for use in treating Bordetella bronchiseptica infections in non-human animals. The present invention also relates in certain embodiments to an immunogenic composition comprising a Bordetella sp. adenylate cyclase toxin (CyaA) vector carrying at least one antigen of Bordetella bronchiseptica.
